Clearing and Masking Agents in Pretargeting Strategies

Markus Staudt; Matthias M Herth

doi:10.3390/ph16040497

Clearing and Masking Agents in Pretargeting Strategies

Markus Staudt^*, Matthias M Herth

^*Corresponding author for this work

Department of Clinical Physiology, Nuclear Medicine & PET

Abstract

'Pretargeting' led to increased target-to-background ratios of nanomedicines in short timeframes. However, clearing or masking agents are needed to reach the full potential of pretargeted approaches. This review gives an overview of clearing and masking agents employed in pretargeting strategies in both preclinical and clinical settings and discusses how these agents work.

Original language	English
Article number	497
Journal	Pharmaceuticals (Basel, Switzerland)
Volume	16
Issue number	4
ISSN	1424-8247
DOIs	https://doi.org/10.3390/ph16040497
Publication status	Published - 27 Mar 2023

Access to Document

10.3390/ph16040497

Cite this

@article{dacd2c464418422eb87156a83fc3f57b,

title = "Clearing and Masking Agents in Pretargeting Strategies",

abstract = "'Pretargeting' led to increased target-to-background ratios of nanomedicines in short timeframes. However, clearing or masking agents are needed to reach the full potential of pretargeted approaches. This review gives an overview of clearing and masking agents employed in pretargeting strategies in both preclinical and clinical settings and discusses how these agents work.",

author = "Markus Staudt and Herth, {Matthias M}",

year = "2023",

month = mar,

day = "27",

doi = "10.3390/ph16040497",

language = "English",

volume = "16",

journal = "Pharmaceuticals (Basel, Switzerland)",

issn = "1424-8247",

publisher = "M D P I AG",

number = "4",

}

TY - JOUR

T1 - Clearing and Masking Agents in Pretargeting Strategies

AU - Staudt, Markus

AU - Herth, Matthias M

PY - 2023/3/27

Y1 - 2023/3/27

N2 - 'Pretargeting' led to increased target-to-background ratios of nanomedicines in short timeframes. However, clearing or masking agents are needed to reach the full potential of pretargeted approaches. This review gives an overview of clearing and masking agents employed in pretargeting strategies in both preclinical and clinical settings and discusses how these agents work.

AB - 'Pretargeting' led to increased target-to-background ratios of nanomedicines in short timeframes. However, clearing or masking agents are needed to reach the full potential of pretargeted approaches. This review gives an overview of clearing and masking agents employed in pretargeting strategies in both preclinical and clinical settings and discusses how these agents work.

UR - http://www.scopus.com/inward/record.url?scp=85154573666&partnerID=8YFLogxK

U2 - 10.3390/ph16040497

DO - 10.3390/ph16040497

M3 - Review

C2 - 37111254

SN - 1424-8247

VL - 16

JO - Pharmaceuticals (Basel, Switzerland)

JF - Pharmaceuticals (Basel, Switzerland)

IS - 4

M1 - 497

ER -

Clearing and Masking Agents in Pretargeting Strategies

Abstract

Access to Document

Other files and links

Fingerprint

Cite this